Defining NASH from a multi-omics systems biology perspective

Research output: Contribution to journal › Review › Research › peer-review

Standard

Defining NASH from a multi-omics systems biology perspective. / Niu, Lili; Sulek, Karolina; Vasilopoulou, Catherine G.; Santos, Alberto; Wewer Albrechtsen, Nicolai J.; Rasmussen, Simon; Meier, Florian; Mann, Matthias.

In: Journal of Clinical Medicine, Vol. 10, No. 20, 4673, 2021.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Niu, L, Sulek, K, Vasilopoulou, CG, Santos, A, Wewer Albrechtsen, NJ, Rasmussen, S, Meier, F & Mann, M 2021, 'Defining NASH from a multi-omics systems biology perspective', Journal of Clinical Medicine, vol. 10, no. 20, 4673. https://doi.org/10.3390/jcm10204673

APA

Niu, L., Sulek, K., Vasilopoulou, C. G., Santos, A., Wewer Albrechtsen, N. J., Rasmussen, S., Meier, F., & Mann, M. (2021). Defining NASH from a multi-omics systems biology perspective. Journal of Clinical Medicine, 10(20), [4673]. https://doi.org/10.3390/jcm10204673

Vancouver

Niu L, Sulek K, Vasilopoulou CG, Santos A, Wewer Albrechtsen NJ, Rasmussen S et al. Defining NASH from a multi-omics systems biology perspective. Journal of Clinical Medicine. 2021;10(20). 4673. https://doi.org/10.3390/jcm10204673

Author

Niu, Lili ; Sulek, Karolina ; Vasilopoulou, Catherine G. ; Santos, Alberto ; Wewer Albrechtsen, Nicolai J. ; Rasmussen, Simon ; Meier, Florian ; Mann, Matthias. / Defining NASH from a multi-omics systems biology perspective. In: Journal of Clinical Medicine. 2021 ; Vol. 10, No. 20.

Bibtex

@article{a09331171ec84bbfa38cbc5e0317e382,
title = "Defining NASH from a multi-omics systems biology perspective",
abstract = "Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.",
keywords = "Biomarker discovery, Liver disease, Machine learning, Multi-omics, NAFLD, Systems biology",
author = "Lili Niu and Karolina Sulek and Vasilopoulou, {Catherine G.} and Alberto Santos and {Wewer Albrechtsen}, {Nicolai J.} and Simon Rasmussen and Florian Meier and Matthias Mann",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/jcm10204673",
language = "English",
volume = "10",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "20",

}

RIS

TY - JOUR

T1 - Defining NASH from a multi-omics systems biology perspective

AU - Niu, Lili

AU - Sulek, Karolina

AU - Vasilopoulou, Catherine G.

AU - Santos, Alberto

AU - Wewer Albrechtsen, Nicolai J.

AU - Rasmussen, Simon

AU - Meier, Florian

AU - Mann, Matthias

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.

AB - Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.

KW - Biomarker discovery

KW - Liver disease

KW - Machine learning

KW - Multi-omics

KW - NAFLD

KW - Systems biology

U2 - 10.3390/jcm10204673

DO - 10.3390/jcm10204673

M3 - Review

C2 - 34682795

AN - SCOPUS:85116795098

VL - 10

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 20

M1 - 4673

ER -

ID: 283756576